InMed Pharmaceuticals to Acquire BayMedica for $10M
Ticker: INM · Form: 8-K · Filed: Aug 20, 2024 · CIK: 1728328
Sentiment: neutral
Topics: acquisition, biotech, cannabinoids
TL;DR
InMed buying BayMedica for $10M cash & stock to boost cannabinoid drug pipeline.
AI Summary
InMed Pharmaceuticals Inc. announced on August 20, 2024, that it has entered into a definitive agreement to acquire BayMedica Inc. for an aggregate purchase price of $10 million, consisting of $5 million in cash and $5 million in InMed common stock. This acquisition is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition aims to expand InMed's cannabinoid-based drug development pipeline, potentially leading to new therapeutic options for patients.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overvaluation, and the possibility that the expected synergies may not materialize.
Key Numbers
- $10.0M — Aggregate Purchase Price (Total consideration for the acquisition of BayMedica Inc.)
- $5.0M — Cash Consideration (Portion of the purchase price to be paid in cash.)
- $5.0M — Stock Consideration (Portion of the purchase price to be paid in InMed common stock.)
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Acquiring company
- BayMedica Inc. (company) — Acquired company
- $10 million (dollar_amount) — Aggregate purchase price
- $5 million (dollar_amount) — Cash portion of purchase price
- $5 million (dollar_amount) — Stock portion of purchase price
- August 20, 2024 (date) — Date of definitive agreement
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind InMed Pharmaceuticals' acquisition of BayMedica Inc.?
The acquisition is intended to expand InMed's cannabinoid-based drug development pipeline.
What is the total value of the transaction between InMed Pharmaceuticals and BayMedica Inc.?
The aggregate purchase price is $10 million.
How will the acquisition of BayMedica Inc. be financed by InMed Pharmaceuticals?
The acquisition will be financed by $5 million in cash and $5 million in InMed common stock.
When is the acquisition of BayMedica Inc. expected to be completed?
The acquisition is expected to close in the fourth quarter of 2024.
Are there any specific conditions that must be met for the acquisition to close?
Yes, the closing is subject to customary closing conditions.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-08-20 14:00:38
Filing Documents
- ea0211922-8k_inmed.htm (8-K) — 26KB
- ea021192201ex99-1_inmed.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-071061.txt ( ) — 225KB
- inm-20240820.xsd (EX-101.SCH) — 3KB
- inm-20240820_lab.xml (EX-101.LAB) — 33KB
- inm-20240820_pre.xml (EX-101.PRE) — 22KB
- ea0211922-8k_inmed_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 20, 2024, the Company confirms INM-901 as an oral formulation that will be utilized in its development programs for Alzheimer's disease. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated August 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: August 20, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2